Start Date
Immediate
Expiry Date
03 Jul, 25
Salary
0.0
Posted On
03 Apr, 25
Experience
0 year(s) or above
Remote Job
Yes
Telecommute
Yes
Sponsor Visa
No
Skills
Good communication skills
Industry
Pharmaceuticals
AVAILABLE DOCUMENTS
Attached documents are available under links. Clicking a document link will initialize its download.
Please note that job descriptions are not exhaustive, and you may be asked to take on additional duties that align with the key responsibilities mentioned above.
We reserve the right to close the advert prior to the closing date stated should we receive a high volume of applications. It is therefore advisable that you submit your application as early as possible to avoid disappointment.
If you encounter any technical issues while applying online, please don’t hesitate to email us at support.jobs@imperial.ac.uk. We’re here to help.
ABOUT THE ROLE
We are looking for a successful and dynamic Senior Programme Manager to lead on a National Institute of Health Research (NIHR) follow-on study. This study, entitled PREVENT (Prevention of Epilepsy by Reducing Neonatal Encephalopathy), involved 60,000 women from several hospitals in India and was funded by an NIHR RIGHT program grant (£3.4 million; 2019-2024). It is led by Professor Sudhin Thayyil in the Centre for Perinatal Neuroscience, where the research focuses on hypoxic ischemic encephalopathy, a birth related brain injury which impacts around three million babies every year, predominantly in low and middle-income countries.
WHAT YOU WOULD BE DOING
You will be involved in supporting data analysis, coordinating with study investigators, parents, the wider public, policymakers, and leading bodies, including the World Health Organisation, for the dissemination of the study results. This is the world’s largest study on babies with birth-related brain injury. You will also help develop the study protocol and obtain necessary regulatory approvals for a newly funded NIHR Global Health Group (£3 million; 2025-2029) called CONNECTIONS (Consortium for Neuroprotection Trials in South Asia), and the other trials within the Centre.